We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




DNA Sequencing at the Doctor's Office

By LabMedica International staff writers
Posted on 21 Oct 2009
As DNA testing expands and the cost and speed of sequencing equipment improves, it is not out of reach that the half-million dollar sequencers now only available in the best research labs may find their way into routine hospital and physician office labs throughout the United States over the next decade, according to recent market research.

These are the findings of Kalorama Information (New York, NY, USA), a healthcare market research firm in a recent report.

"With rapidly falling costs and increasing scientific discoveries, it is expected to reach a level where few other technologies can compete with sequencers,” said Justin Saeks, biotech analyst for Kalorama Information and author of the report. More...
"Over the next decade, the largest opportunity for sequencing technologies may actually be in the doctor's office or hospital.”

According to the report, progress has been strong both in the development of better machines and in the mapping of the fully sequenced genomes, which help to justify the use of sequencers. The research noted that most of the 900 sequencing projects in the Genomes OnLine Database (GOLD) at the end of 2008 were bacterial and viral, and many of these could have clinical applications. Approximately one-third of sequencing projects were aimed at a specific disease. The growth in sequenced genomes points to a promising future for the technology, especially when combined with the downward movement in equipment pricing.

Indeed, in 2009 the Dover (Salem NH, USA) Polonator was released at one-third of the price. Another positive trend for the industry is the growth of DNA testing in laboratories. While it constitutes a small portion of overall testing in terms of revenues, the growth of molecular testing as a segment is faster than traditional segments, and points to a role for sequencers in the future.

Nonetheless, Kalorama Information noted that there are many steps along the way from the high-level research lab to the hospital and physician office. Clinical products are very different from a marketing and regulatory perspective than research products. One key to making the vision of the future a reality, according to Mr. Saeks, is that sequencing companies should partner with those who know their way around these markets already. "Sequencing companies will need to be aware of the regulatory processes and other pitfalls, and this is best achieved by partnering with established diagnostics companies,” he said.

Kalorama Information supplies independent market research in the life sciences, as well as custom research services.

Related Links:

Kalorama Information
Genomes OnLine Database



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.